<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Microbiology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Microbiology</JournalTitle>
      <Issn>2008-3289</Issn>
      <Volume>18</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="epublish">
        <Year>2026</Year>
        <Month>10</Month>
        <Day>05</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Mutation-induced penicillin binding protein 2A inactivation through CRISPR-dCas9 gene editing in methicillin-resistant S. aureus</title>
    <FirstPage>741</FirstPage>
    <LastPage>751</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Arooj</FirstName>
        <LastName>Khan</LastName>
        <affiliation locale="en_US">Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan</affiliation>
      </Author>
      <Author>
        <FirstName>Adnan</FirstName>
        <LastName>Iqbal</LastName>
        <affiliation locale="en_US">Institute-National Research Institute, Radzikow, Blonie, Poland</affiliation>
      </Author>
      <Author>
        <FirstName>Husnain</FirstName>
        <LastName>Athar</LastName>
        <affiliation locale="en_US">Department of Pediatrics, Punjab Institute of Cardiology, Lahore, Pakistan</affiliation>
      </Author>
      <Author>
        <FirstName>Ahsan</FirstName>
        <LastName>Sheikh</LastName>
        <affiliation locale="en_US">Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan; Centre for Research in Molecular Medicine (CRiMM), University of Lahore, Lahore, Pakistan</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2025</Year>
        <Month>11</Month>
        <Day>20</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2026</Year>
        <Month>07</Month>
        <Day>08</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background and Objectives: The global rise of antimicrobial resistance threatens effective treatment of bacterial infections. Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen whose resistance to &#x3B2;-lactam antibiotics is primarily mediated by the mecA gene, encoding the low-affinity penicillin-binding protein PBP2a. This study aimed to investigate whether CRISPR-dCas9-mediated targeting of mecA could suppress resistance-associated gene expression and restore &#x3B2;-lactam susceptibility in MRSA.
Materials and Methods: Seven target sites within mecA, comprising two non-coding and five coding regions, were selected for CRISPR-dCas9 targeting. The effects of gene interference were evaluated using antibiotic disk diffusion assays, minimum inhibitory concentration (MIC) testing with gradient E-strips, RT-PCR, and Sanger sequencing.
Results: Targeting non-coding regions suppressed mecA transcription and reduced PBP2a production, whereas targeting coding regions generated mutations associated with dysfunctional PBP2a. CRISPR-dCas9 treatment significantly reduced mecA expression and increased MRSA susceptibility to &#x3B2;-lactam antibiotics, particularly ampicillin and cefixime. MIC values decreased by up to 12-fold and 6-fold, respectively (p&lt;0.05).
Conclusion: CRISPR-dCas9-mediated targeting of mecA effectively reduced &#x3B2;-lactam resistance in MRSA. This approach demonstrates potential for precision-based antimicrobial resistance management and warrants further investigation as a strategy for combating drug-resistant bacterial infections.</abstract>
    <web_url>https://ijm.tums.ac.ir/index.php/ijm/article/view/5951</web_url>
    <pdf_url>https://ijm.tums.ac.ir/index.php/ijm/article/download/5951/1935</pdf_url>
  </Article>
</Articles>
